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1  | INTRODUCTION
Acromegaly is a chronic and disfiguring hormonal disease caused by a be-
nign growth hormone (GH) secreting pituitary adenoma in most of the 
cases.1 Cardiovascular complications are associated with the long- term 
presence of GH and insulin- like growth factor I (IGF- I) and are the most 
common causes of morbidity and mortality in acromegaly.2 Hypertension, 
left ventricular hypertrophy (LVH), and consequent heart failure are 
among the most common cardiovascular complications of acromegaly, 
but specific arrhythmias and mitral valve regurgitation can also occur.3–5
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Introduction: Acromegaly is a chronic and disfiguring hormonal disease caused by a 
benign growth hormone- secreting pituitary adenoma in most of the cases. The 
objective of this study was to investigate three- dimensional (3D) speckle tracking 
echocardiography (3DSTE)- derived left atrial (LA) volumetric and functional proper-
ties in patients with acromegaly. It was also examined whether the activity of 
acromegaly is associated with further alterations in these LA parameters.
Methods: A total of 23 patients with acromegaly were involved in this study. Due to 
inadequate image quality, 4 patients were excluded from the 3DSTE analysis. The 
mean age of the remaining acromegalic subjects was 58.5 ± 13.1 years (7 males). The 
control group consisted of 21 age- and gender- matched healthy subjects (mean age 
51.8 ± 10.3 years, 10 males).
Results: Maximum (44.8 ± 12.7 mL vs 78.7 ± 25.4 mL, P < .05), minimum 
(24.1 ± 9.0 mL vs 44.5 ± 15.5 mL, P < .05), and preatrial contraction (35.5 ± 11.2 mL 
vs 66.0 ± 22.8 mL, P < .05) LA volumes were significantly different between all acro-
megaly patients compared with controls. Increased peak global and mean segmental 
radial and 3D strains and decreased LA circumferential strain (CS) could be detected 
in all acromegaly patients as compared to healthy subjects. Significant correlation 
could be detected between insulin- like growth factor 1 (IGF- 1) index and peak supe-
rior LA-CS (r = .49, P = .05) in acromegaly.
Conclusion: Acromegaly is associated with increased LA volumes and changes in LA 
functional properties.
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Three- dimensional (3D) speckle tracking echocardiography 
(3DSTE) offers clinicians a new noninvasive tool in character-
izing and understanding preclinical cardiac involvement via 3D 
strain analysis, which is unique to this tool.6 3DSTE is a vali-
dated method for left atrial (LA) quantification as compared to 
two-dimensional (2D) echocardiography, 2DSTE, and volumet-
ric real- time 3D echocardiography (RT3DE).6–8 The number of 
studies concerning acromegaly- associated LA volumetric and 
functional changes is limited.9 The objective of this study was 
to investigate 3DSTE- derived LA volumetric and functional 
properties in patients with acromegaly. It was also examined 
whether the activity of acromegaly is associated with further 
alterations in these LA parameters.
2  | METHODS
2.1 | Patient­population
A total of 23 patients with acromegaly were involved in this study. Due 
to inadequate image quality, 4 patients were excluded from the 3DSTE 
analysis. The mean age of the remaining acromegalic subjects was 
58.5 ± 13.1 years, from which 7 subjects were male. Acromegaly was 
diagnosed according to relevant clinical standards: typical clinical fea-
tures and elevated serum GH and/or IGF- 1 levels not suppressible with 
oral glucose tolerant test (OGTT, 75 g).5 The acromegaly patient group 
was further divided into two subgroups based on the activity of the dis-
ease. Patients were allocated to the active subgroup if serum GH levels 
F IGURE  1 Three- dimensional (3D) speckle tracking echocardiographic assessment of the left atrium (LA) is displayed in an acromegaly 
patient. Apical four- chamber view (A), apical two- chamber view (B), short- axis view at basal (C3), midatrial (C5), and superior left atrial level 
(C7) are presented together with a 3D model of the LA and calculated volumetric data. Time—LA global volume (dashed line) and Time—LA 
circumferential segmental strain curves (colorized lines). EDV = end-diastolic volume; ESV = end-systolic volume; EF = ejection fraction; 
LA = left atrium
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were above the standard threshold.5,10 Control group consisted of 21 
age- and gender- matched healthy subjects (mean age 51.8 ± 10.3 years, 
10 male). All data of acromegalic patients were taken from the 
MAGYAR- Path Study (Motion Analysis of the heart and Great vessels bY 
three- dimensionAl speckle- tRacking echocardiography in Pathological 
cases), which was created to assess diagnostic and prognostic value of 
3DSTE- derived parameters (“magyar” means “Hungarian” in Hungarian 
language). The study complied with the Declaration of Helsinki and was 
approved by the institutional human research committee. All patients 
and control subjects gave informed consent.
2.2 | Two-­dimensional­Doppler­and­tissue­Doppler­
echocardiography
All acromegalic patients and negative control subjects underwent 
a complete two- dimensional (2D) transthoracic echocardiographic 
assessment using a Toshiba Artida imaging system (Toshiba 
Medical Systems, Tokyo, Japan) with a PST- 30SBP (1–5 MHz) 
phased array transducer. According to routine clinical standards, 
complete 2D Doppler study was performed in all cases including 
quantification of LV dimensions, volumes, ejection fraction, and 
LA dimensions.11
2.3 | Three-­dimensional­speckle­tracking­
echocardiography
Three- dimensional speckle tracking echocardiography measurements 
were performed using the same Toshiba Artida echocardiography equip-
ment with a PST- 25SX matrix- array transducer with 3DSTE capability. 
Full- volume 3D datasets were obtained by combining 6 R- wave triggered 
wedge- shaped subvolumes during 6 cardiac cycles. Subvolumes were 
registered during a single breath- hold and constant RR interval from the 
apical window. Sector widths of the subvolumes were chosen to be as 
narrow as possible thus improving spatial resolution and providing im-
proved endocardial border detection. Registered datasets were analyzed 
off line using 3D Wall Motion Tracking software version 2.7 (Toshiba 
Medical Systems). The software chose an apical four- chamber (AP4CH) 
view and an apical two- chamber (AP2CH) view together with 3 short- axis 
Controls­(n­=­21)
Acromegaly­patients­
(n­=­19) P-­value
Risk factors
Age (years) 51.8 ± 10.3 58.5 ± 13.1 .08
Male gender (%) 10 (48) 7 (37) .54
BSA (m2) 2.0 ± 0.2 2.1 ± 0.3 .26
Hypertension (%) 0 (0) 11 (58) <.0001
Hypercholesterolemia (%) 0 (0) 8 (42) .001
Diabetes mellitus (%) 0 (0) 3 (16) .1
Medications
β- blockers (%) 0 (0) 5 (26) .02
ACE inhibitors (%) 0 (0) 8 (42) .001
ARB (%) 0 (0) 5 (30) .02
Diuretics (%) 0 (0) 6 (32) .007
Two- dimensional echocardiography
LA diameter (mm) 33.9 ± 3.4 42.1 ± 5.6 <.0001
LA diameter/BSA (mm/m2) 17.8 ± 2.3 20.8 ± 3.3 .005
LA volume/BSA (mL/m2) 25.1 ± 8.3 31.5 ± 13.9 .08
LV end- diastolic diameter (mm) 47.4 ± 7.3 51.1 ± 5.4 .07
LV end- diastolic volume (mL) 107.6 ± 38.6 128.3 ± 28.6 .06
LV end- systolic diameter (mm) 30.3 ± 4.8 32.0 ± 5.0 .27
LV end- systolic volume (mL) 36.3 ± 13.0 42.7 ± 15.7 .17
Interventricular septum (mm) 9.2 ± 1.7 10.1 ± 1.5 .07
LV posterior wall (mm) 9.4 ± 1.9 10.9 ± 1.9 .02
LV ejection fraction (%) 65.4 ± 6.3 66.7 ± 7.7 .56
E velocity (cm/s) 66.5 ± 14.1 62.3 ± 10.4 .30
A velocity (cm/s) 65.5 ± 15.9 79.3 ± 15.7 .01
E/A ratio 1.1 ± 0.3 0.8 ± 0.2 .002
ARB = angiotensine II receptor blocker; ACE = angiotensine- converting enzyme inhibitor; 
BSA = body surface area; LA = left atrium; LV = left ventricle.
TABLE  1 Demographic, clinical, and 
two- dimensional echocardiographic data 
of patients with acromegaly and controls
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views of the LA at end- diastole automatically. After image optimization, 
the reader detected the endocardial border by placing 6–8 markers to 
the edge of the septum–mitral annulus (MA) toward the edge of the lat-
eral wall- MA (Figures 1 and 2). Then, the software automatically recon-
structed the endocardial surface of the LA and performed volumetric 
and strain analyses. The frame rate changed between 27 and 30/s, and 
volume rates were between 27 and 30 vps during 3DSTE assessments.
2.4 | 3DSTE-­derived­LA­volumetric­measurements
The following volumetric data were obtained from the 3DSTE data-
sets (Figure 1):
• End-systolic maximum LA volume (Vmax, before mitral valve 
opening).
• Early diastolic LA volume before atrial contraction (VPreA, at the 
time of the P-wave on the ECG).
• End-diastolic minimum LA volume (Vmin, before mitral valve 
closure).
Based on the acquired volumetric data, several functional parame-
ters were calculated representing systolic reservoir and diastolic con-
duit and active contraction LA functional phases.8
2.4.1 | Reservoir­function
• Total stroke volume (SV) = Vmax	−	Vmin
• Total emptying fraction (EF) = Total SV/Vmax
2.4.2 | Conduit­function
• Passive SV = Vmax	−	VpreA
• Passive EF = Passive SV/Vmax
2.4.3 | Active­contraction
• Active SV = VpreA	−	Vmin
• Active EF = Active SV/VpreA
2.5 | 3DSTE-­derived­LA­strain­assessments
Using the same 3D datasets, the software obtained several lin-
ear (radial [RS], longitudinal [LS], and circumferential [CS]) and 
two complex (3D [3DS] and area [AS]) LA strains automatically. 
Global, mean segmental, and regional strains were also calcu-
lated. Peak strains were measured during the LA reservoir phase 
TABLE  2 Comparison of 3DSTE- derived volumetric left atrial parameters between patients with acromegaly and controls
Controls­(n­=­21)
Acromegaly­patients­
(n­=­19)
Active­acromegaly­patients­
(n­=­11)
Inactive­acromegaly­
patients­(n­=­8)
Calculated volumes
Vmax (mL) 44.8 ± 12.7 78.7 ± 25.4* 74.6 ± 26.0* 84.2 ± 25.2*
Vmax/BSA (mL/m
2) 23.5 ± 7.7 38.7 ± 13.0* 37.8 ± 15.7* 39.9 ± 9.0*
Vmin (mL) 24.1 ± 9.0 44.5 ± 15.5* 44.4 ± 16.5* 44.6 ± 15.3*
Vmax/BSA (mL/m
2) 12.5 ± 4.8 22.0 ± 8.7* 22.6 ± 10.3* 21.3 ± 6.4*
VpreA (mL) 35.5 ± 11.2 66.0 ± 22.8* 62.5 ± 23.8* 70.7 ± 21.9*
Vmax/BSA (mL/m
2) 18.8 ± 6.8 32.5 ± 12.1* 31.8 ± 14.7* 33.5 ± 8.1*
Stroke volumes
TASV (mL) 20.7 ± 6.8 34.2 ± 12.8* 30.3 ± 12.1* 39.6 ± 12.5*
TASV/BSA (mL/m2) 11.0 ± 4.2 16.6 ± 5.7* 15.2 ± 6.4 18.6 ± 4.1*
PASV (mL) 9.3 ± 3.9 12.7 ± 6.8 12.1 ± 7.9 13.5 ± 5.3*
PASV/BSA (mL/m2) 4.7 ± 2.3 6.1 ± 2.9 6.0 ± 3.4 6.3 ± 2.2
AASV (mL) 11.4 ± 5.5 21.5 ± 9.6* 18.2 ± 9.7 26.1 ± 7.9*
AASV/BSA (mL/m2) 6.3 ± 3.5 10.5 ± 4.5* 9.2 ± 5.4 12.3 ± 2.3*
Emptying fractions
TAEF (%) 46.9 ± 10.2 43.2 ± 8.7 40.2 ± 8.0 47.3 ± 8.5
PAEF (%) 21.4 ± 9.0 16.3 ± 7.7 16.5 ± 9.2 16.1 ± 5.6
AAEF (%) 32.5 ± 10.4 31.9 ± 9.4 28.0 ± 9.7** 37.5 ± 6.0
AASV = active atrial stroke volume; AAEF = active atrial emptying fraction; BSA = body surface area; PAEF = passive atrial emptying fraction; 
PASV = passive atrial stroke volume; TAEF = total atrial emptying fraction; TASV = total atrial stroke volume; Vmax = maximum left atrial volume; 
Vmin = minimum left atrial volume; VpreA = left atrial volume before atrial contraction.
*P < .05 vs controls.
**P < .05 vs inactive acromegaly.
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in systole, while strains at atrial contraction were obtained at 
end- diastole (LA systole) to characterize LA booster pump func-
tion (Figure 1).7
2.6 | Statistical­analysis
All data are reported as mean ± standard deviation. P values 
<.05 were considered significant. For categorical variables, 
Fisher’s exact test was used. Shapiro–Wilks test was used to 
test normal distribution in every dataset. Homogeneity of vari-
ance was assessed using Levene’s test for equality of variances. 
Student’s t test was used for datasets following normal distribu-
tion and Mann–Whitney–Wilcoxon test was used for datasets 
that were not normally distributed. Correlations were assessed 
by calculating Pearson’s correlation coefficients. RStudio was 
used for statistical analysis (RStudio Team, RStudio: Integrated 
Development for R. RStudio, Inc., Boston, MA, 2015). For of-
fline data analysis and graph creation, a commercial software 
package was used (MATLAB 8.6, The MathWorks Inc., Natick, 
MA, 2015).
3  | RESULTS
3.1 | Demographic­data­of­patients­with­acromegaly
Demographic and clinical data are presented in Table 1. Across 
all acromegalic patients, the mean level of serum GH was 
5.73 ± 6.89 ng/mL and mean IGF- 1 serum concentration was 
332 ± 210 ng/mL. Patients who were prior hypophysectomy or 
who underwent the surgery but had hormonally active remnant 
tissue or medically managed patients having elevated IGF- 1 level 
despite long- acting somatostatine analogue therapy were placed 
in the active acromegalic subgroup (n = 11). In this group, the 
mean level of IGF- 1 was 418 ± 207 ng/mL, and mean GH level was 
5.52 ± 3.94 ng/mL. Patients who had normal IGF- 1 and/or normal 
GH serum levels or normal GH nadir levels after OGTT during 
pegvisomant, bromocriptine, or long- acting somatostatin analogue 
therapy or patients who underwent successful hypophysectomy 
made up the inactive acromegalic subgroup (n = 8). In this group, 
the mean level of IGF- 1 was 176 ± 102 ng/mL, mean GH level was 
6.11 ± 10.98 ng/mL, and mean nadir hGH level after OGTT was 
2.08 ± 2.06 ng/mL.
TABLE  3 Comparison of 3DSTE- derived regional peak left atrial strain parameters between patients with acromegaly and controls
Controls­(n­=­21)
Acromegaly­patients­
(n­=­19)
Active­acromegaly­patients­
(n­=­11)
Inactive­acromegaly­
patients­(n­=­8)
Mean segmental
RS (%) −20.5	±	7.5 −26.1	±	7.0* −26.0	±	7.7 −26.3	±	6.6
CS (%) 31.7 ± 11.7 25.0 ± 7.8* 23.6 ± 7.6* 27.0 ± 8.1
LS (%) 27.3 ± 6.6 24.5 ± 6.0 23.1 ± 6.2 26.4 ± 5.5
3DS (%) −14.7	±	6.3 −19.4	±	5.2* −19.4	±	5.5* −19.4	±	5.1*
AS (%) 61.2 ± 20.0 51.0 ± 14.7 47.6 ± 12.3* 56.5 ± 16.9
Regional
RSbasal (%) −23.4	±	11.2 −23.4	±	9.1 −24.4	±	9.7 −22.1	±	8.8
RSmidatrial (%) −21.5	±	9.6 −27.8	±	7.8* −26.6	±	8.0 −29.3	±	7.7*
RSsuperior (%) −18.5	±	13.0 −27.8	±	10.2* −27.5	±	11.6* −28.1	±	8.7*
CSbasal %) 35.9 ± 9.5 27.4 ± 9.9
* 25.9 ± 8.8* 29.6 ± 11.4
CSmidatrial (%) 28.9 ± 11.5 24.0 ± 7.7 22.1 ± 8.5 26.6 ± 6.0
CSsuperior (%) 30.1 ± 16.2 23.0 ± 16.1 22.6 ± 12.4 23.6 ± 21.2
LSbasal (%) 17.6 ± 7.7 13.9 ± 6.1 13.0 ± 7.0 15.1 ± 4.7
LSmidatrial %) 37.7 ± 10.4 37.1 ± 9.3 34.0 ± 8.2 41.3 ± 9.5
LSsuperior (%) 23.4 ± 9.9 21.5 ± 12.9 21.9 ± 14.9 21.0 ± 10.6
3DSbasal (%) −17.4	±	11.0 −18.3	±	7.9 −19.4	±	8.2 −16.7	±	7.7
3DSmidatrial (%) −14.2	±	7.2 −19.3	±	5.0* −19.1	±	5.4 −19.7	±	5.4
3DSsuperior %) −12.1	±	10.0 −21.0	±	9.2* −19.6	±	10.2* −22.9	±	8.0*
ASbasal (%) 51.2 ± 16.2 38.8 ± 12.9* 36.4 ± 10.3* 42.2 ± 16.1
ASmidatrial (%) 71.3 ± 25.3 65.4 ± 18.5 58.2 ± 16.8** 75.3 ± 16.7
ASsuperior (%) 62.8 ± 34.2 48.9 ± 35.0 48.4 ± 29.5 49.6 ± 43.8
3DS = three- dimensional strain; AS = area strain; CS = circumferential strain; LS = longitudinal strain; RS = radial strain.
*P < .05 vs controls.
**P < .05 vs inactive acromegaly.
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3.2 | Two-­dimensional­echocardiographic­data
Out of 2D echocardiography parameters, LA diameter, body sur-
face area (BSA)- indexed LA diameter, and LV posterior wall thick-
ness were significantly different between the patient populations 
(P < .0001, P = .005, P = .02, respectively). Early filling transmitral 
flow velocity (E) was not significantly different; however, late fill-
ing transmitral flow velocity (A) and E/A ratio differed significantly 
between controls and acromegaly patients (P = .01 and P = .002, re-
spectively). Among all acromegaly patients, mild- to- moderate mitral 
regurgitation was present in 7 cases (Table 1).
3.3 | 3DSTE-­derived­volumes­and­volume-­based­LA­
functional­properties
All three LA volumetric parameters (Vmax, VpreA, Vmin) were sig-
nificantly different between all acromegaly patients (P	≤	.0001,	
P	≤	.0001,	 P	≤	.0001,	 respectively),	 active	 (P = .004, P = .004, 
P	≤	.0001,	 respectively),	 and	 inactive	 acromegaly	 patients	
(P	≤	.0001,	P	≤	.0001,	P = .0001, respectively) compared with neg-
ative controls. Similarly, all BSA- indexed Vmax, VpreA, and Vmin were 
significantly different between all acromegaly patients (P = .0003, 
P = .0003, P = .0004, respectively), active (P = .03, P = .008, 
P = .0004, respectively), and inactive acromegaly patients 
(P = .0003, P = .002, P = .0006, respectively). Out of LA volume- 
based functional properties, only total and active SVs differed 
significantly between all acromegaly patients and healthy controls 
(P = .0003, P = .0002, respectively). BSA- indexed total and active 
SVs showed similar differences (P = .003, P = .006, respectively). 
Only total SV was significantly increased in active acromegaly pa-
tients as compared to that of the control group (P = .03). Significant 
differences could be demonstrated between inactive acromegaly 
patients and control patients regarding all three stroke volumes 
(total, passive, and active SVs) (P < .0001, P = .03, P < .0001, re-
spectively). From BSA- indexed parameters, total and active SVs 
differed significantly (P = .0006, P = .0004, respectively). Between 
the active and inactive acromegaly patient subgroups, only active 
EF differed significantly (P = .03) (Table 2). There was no signifi-
cant correlation between volumetric parameters and mean GH, 
IGF- 1, or IGF- 1 index.
3.4 | 3DSTE-­derived­peak­LA­strain­parameters
Increased global and mean segmental peak RS (P = .04, P = .02) and 
3DS (P = .02, P = .02) and decreased global and mean segmental CS 
(P = .02, P = .04) could be detected in all acromegaly patient groups 
as compared to the group of healthy subjects (Table 3, Figure 3). 
Global and mean segmental peak CS (P = .02, P = .05) and mean seg-
mental AS (P = .05) were found to be diminished, while mean seg-
mental 3DS were increased (P = .05) in active acromegaly patients 
as compared to controls. Significantly increased mean segmental 
3DS were found in data of the inactive acromegaly subgroup com-
pared with healthy subjects (P = .03) (Table 3). Regional differences 
in all peak strains between all acromegaly patients, active and inac-
tive acromegaly patients, and controls are demonstrated in Table 3. 
Significant correlation could be detected in the acromegaly group 
F IGURE  2 Three- dimensional (3D) speckle tracking echocardiographic assessment of all types of (segmental) strains (colored lines) and 
left atrial volume change (dashed white line) over cardiac cycle in a control subject and in active and inactive acromegalics
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between IGF- 1 index and superior peak CS (r = .49, P = .05). In the 
active acromegaly subgroup, significant correlations were found be-
tween the basal peak CS and serum IGF- 1 and IGF- 1 index levels 
(r = .76, P = .007; r = .69, P = .02) (Figure 4).
3.5 | 3DSTE-­derived­LA­strains­at­atrial­contraction
Increased global and mean segmental 3DS (P = .02, P = .02, respec-
tively) and mean segmental RS and LS (P = .03, P = .02, respec-
tively) could be detected in all acromegaly patients compared with 
controls. While inactive acromegaly patients had the same global 
and mean segmental LA strain parameters as compared to that 
of controls, activity of acromegaly was associated with increased 
global and mean segmental RS (P = .01, P = .007) and 3DS (P = .02, 
P = .03). Moreover, significant differences could be detected be-
tween global and mean segmental RS (P = .01, P = .03) and mean 
segmental 3DS (P = .05) of active and inactive acromegaly patients 
(Table 4, Figure 3). Regional differences in all strains at atrial con-
traction between all acromegaly patients, active and inactive acro-
megaly patients, and controls are demonstrated in Table 4.
4  | DISCUSSION
Acromegaly is a rare, chronic, progressive, and insidious disorder 
characterized by excess secretion of GH and elevated circulating lev-
els of IGF- I, generally caused by a pituitary adenoma.12 Acromegaly 
patients often have established systemic complications at diagnosis 
with increased morbidity and mortality mostly due to cardiovascular 
reasons.13 The pathophysiology underlying cardiac involvement in 
acromegaly is not clearly understood, elevated GH serum levels and 
consequent plasma volume expansion and direct anti- natriuretic ef-
fect, increased peripheral vascular resistance may be the cause. LVH 
and myocardial fibrosis are considered common findings in acromeg-
alic cardiomyopathy in echocardiography studies.14 However, there 
is limited information on LA function in acromegaly.9
Newer echocardiographic modalities including 3D and/or STE 
enable detailed assessment of not only the LV, but atrial functions 
as well.8 3DSTE uses a “block- matching” by strain analysis algo-
rithm to accurately assess volumetric and functional properties of 
the LA during different cardiac cycles.8 Volumetric RT3DE is widely 
regarded as a highly accurate noninvasive method for volumetric 
TABLE  4 Comparison of 3DSTE- derived regional left atrial strain parameters at atrial contraction between patients with acromegaly and 
controls
Controls­(n­=­21)
Acromegaly­patients­
(n­=­19)
Active­acromegaly­patients­
(n­=­11)
Inactive­acromegaly­
patients­(n­=­8)
Mean segmental
RS (%) −9.2	±	5.9 −13.2	±	5.0* −15.3	±	5.2*,** −10.4	±	3.3
CS (%) 15.0 ± 8.6 14.4 ± 5.8 12.7 ± 6.0 16.6 ± 5.1
LS (%) 9.3 ± 4.3 12.1 ± 3.6* 12.2 ± 3.8 12.1 ± 3.6
3DS (%) −6.7	±	5.2 −10.3	±	3.7* −10.8	±	3.7*,** −9.5	±	3.7
AS (%) 21.6 ± 11.7 26.2 ± 9.0 23.6 ± 8.7 29.7 ± 8.8
Regional
RSbasal (%) −10.7	±	7.4 −12.9	±	6.4 −14.1	±	7.4 −11.2	±	4.7
RSmidatrial (%) −8.0	±	7.0 −12.9	±	6.5* −15.6	±	5.6*
,** −9.0	±	6.0
RSsuperior (%) −8.6	±	6.1 −14.2	±	7.2* −16.5	±	7.3* −11.1	±	6.0
CSbasal %) 18.5 ± 8.7 16.0 ± 7.5 14.7 ± 8.6 17.8 ± 5.7
CSmidatrial (%) 12.0 ± 8.4 14.3 ± 6.4 12.9 ± 7.3 16.3 ± 4.6
CSsuperior (%) 11.5 ± 12.4 12.0 ± 11.2 9.6 ± 7.5 15.4 ± 14.7
LSbasal (%) 6.9 ± 5.5 6.7 ± 4.2 5.7 ± 2.7 8.1 ± 5.5
LSmidatrial %) 11.4 ± 6.7 16.8 ± 7.2* 17.7 ± 5.7* 15.6 ± 9.2
LSsuperior (%) 9.8 ± 8.1 13.2 ± 10.5 13.5 ± 12.2 12.8 ± 8.4
3DSbasal (%) −8.2	±	6.7 −10.2	±	5.5 −10.3	±	5.2 −10.0	±	6.3
3DSmidatrial (%) −4.9	±	5.4 −10.1	±	4.6* −10.7	±	4.6* −9.3	±	4.8*
3DSsuperior %) −6.8	±	5.3 −10.7	±	6.4* −11.8	±	7.1* −9.3	±	5.4
ASbasal (%) 20.7 ± 9.2 20.3 ± 6.3 17.8 ± 6.2** 23.8 ± 4.9
ASmidatrial (%) 22.6 ± 12.8 32.3 ± 13.1* 30.9 ± 12.7 34.3 ± 14.7*
ASsuperior (%) 21.7 ± 23.3 25.8 ± 22.5 21.5 ± 17.1 31.7 ± 28.5
3DS = three- dimensional strain; AS = area strain; CS = circumferential strain; LS = longitudinal strain; RS = radial strain.
*P < .05 vs controls.
**P < .05 vs inactive acromegaly.
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measurements of LA due to its high spatial resolution.6 3DSTE and 
RT3DE methodologies were found to be comparable, reproduc-
ible, and interchangeable.15 Also, 3DSTE has several advantages 
compared to 2DSTE. Mochizuki et al compared the two methods 
for LA chamber quantification, and they found that 3DSTE was 
similarly feasible as its 2D counterpart; however, the interobserver 
variability and time required for analysis were shorter in case of 
3DSTE. Moreover, 2DSTE by its nature can only properly assess 
LA longitudinal function; however, 3DSTE is capable of measuring 
wall strains in circumferential direction and thus calculating area 
strain and 3D strain, as well.7 Furthermore, our group previously 
demonstrated the feasibility of 3DSTE in measuring LA volumes 
F IGURE  3 Bar charts showing global left atrial peak strains and strains at atrial contraction among the various groups. Numbers in the 
bars represent the mean strain values of each corresponding group. *P < .05 vs controls; †P < .05 vs inactive acromegaly
F IGURE  4 Significant correlations between IGF- 1/IGF- 1 index and segmental circumferential strain parameters in acromegalics
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and functional properties directly compared to the standard clini-
cal 2D echocardiography technique.8
During the cardiac cycle, LA has a distinct phasic function. It 
serves as a reservoir during LV systole; during early LV diastole, it 
conducts blood from the pulmonary veins to the LV, and in late dias-
tole, the LA augments LV filling through active contraction.16 Total, 
passive, and active SVs and EFs characterize the aforementioned 
LA functional properties, respectively. The complete 3D datasets 
enabled us to calculate global, mean segmental, and regional basal, 
midatrial and superior peak strains, and strains at atrial contraction 
as well for further characterization of the LA reservoir and atrial 
booster pump functions.
In a recent study, LA volumes (maximum, minimum, and presys-
tolic) and LA mechanical functions were not significantly different 
in patients with active acromegaly compared with age- and gender- 
matched healthy controls. Additionally, serum levels of GH and 
IGF- 1 did not correlate with LA mechanical functions.9 A previous 
animal study examined 11 cats with acromegaly; 6 of the subject an-
imals had significantly enlarged LA.17 In a previous study presenting 
3 acromegalic patients with heart failure, the LA was found to be 
enlarged in all three cases.18 To the best of the author’s knowledge, 
there are no studies characterizing 3DSTE- derived LA volumes, 
volume- based functional properties, and strains in acromegaly 
patients. Significantly enlarged 3DSTE- derived LA volumes respect-
ing cardiac cycle could be demonstrated in acromegalic patients as 
compared to controls regardless the activity of disease. Out of the 
functional properties, total and active atrial SVs were significantly 
different, but atrial EFs showed no difference across all acromegaly 
patients compared to healthy controls. The active acromegaly pa-
tients had enhanced atrial SVs on average compared to the healthy 
population, although the difference reached the level of significance 
only in case of the total atrial SV. The inactive acromegaly patient 
subgroup showed significantly augmented atrial SVs compared to 
the control group. Total and active atrial EFs were augmented in the 
inactive acromegaly population compared to the active acromegaly 
group, although only the difference of active atrial EF reached the 
level of significance. These results suggest that after proper treat-
ment, preexisting LA volumetric changes do not recede, although 
enhanced LA SVs might suggest a compensatory mechanism. Strain 
analysis revealed decreased global peak CS and increased global 
peak RS and 3DS in acromegaly. In case of inactive acromegaly, the 
decreased peak CS receded and was not significantly different com-
pared to this parameter of the healthy controls. Mean segmental peak 
LA strains showed similar results. In case of LA, CSs are thought to 
be the most sensitive parameter, and the above- described changes 
might suggest a somewhat reversible atrial dysfunction after proper 
treatment of acromegaly.
The above- described LA changes may be reactive to the LV 
changes that are characteristic in acromegaly. In the early stages, 
hyperkinetic syndrome and LVH are the primary changes (caused by 
increased Ca- sensitivity thus increased myocardial contractility); as 
the disease progresses, LVH becomes more prominent and diastolic 
ventricular filling becomes impaired. In the later stages, extracellular 
collagen deposition and thus reduced systolic and diastolic func-
tion, LV remodeling, and heart failure characterize the clinical pic-
ture.19–22 The remodeling of the LA might also occur, parallel to the 
LVH, but the possible effect of collagen deposition cannot be ruled 
out either. The real mechanism behind the LA volumetric and func-
tional alterations and LA remodeling is not known yet in acromegaly. 
The increased LA volumes and augmented SVs might be due to the 
decreased diastolic filling of the LV; however, the effect of hyper-
tension and a certain degree of mitral regurgitation cannot be ruled 
out as these are common findings in acromegaly. Moreover, age- 
related changes could have an effect, as well. The hormonal changes 
(GH and IGF- 1) might also play a notable part in the remodelation of 
the LA.
4.1 | Limitations
The main limitation of this study is the low number of acromegaly 
patients involved. In the present study, we did not take into account 
for how long the acromegaly was active after the diagnosis, or for 
how long the disease was inactive in case of successful treatment. 
The possible effects of the specific drugs used in the treatment 
of acromegaly on LA volumetric, functional, and strain parameters 
were not explored in this study. In addition, the spatial resolution of 
3DSTE is relatively poor compared to that of 2D echocardiography. 
There are no reference values for 3DSTE- derived LA strain, volu-
metric and functional parameters at this time; therefore, LA data 
of control patients might differ compared to other studies. Due to 
the nature of the software used, only R- wave triggered measure-
ments were possible; even though in case of LA, P- wave triggering 
is superior.23 The software is capable of measuring RS, but in case 
of the atria, it is thought to be a weak parameter due to the thinness 
of atrial walls. Even though 3DSTE is a feasible imaging modality for 
quantifying LA volumetric and strain assessments, further valida-
tion studies with larger populations are warranted.
5  | CONCLUSION
Acromegaly is associated with increased LA volumes and changes in 
LA functional properties.
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